<https://investingnews.com/news/pharmaceutical-investing/pfizer-and-biontech-share-positive-early-data-on-lead-mrna-vaccine-candidate-bnt162b2-against-covid-19/#webpage>
<http://schema.org/description>
"Pfizer and BioNTech today shared additional Phase 1 safety and immunogenicity data from their ongoing US study of the BNT162 mRNA-based vaccine program against SARS-CoV-2, which has advanced into Phase 2/3 evaluation."
<https://investingnews.com/news/pharmaceutical-investing/pfizer-and-biontech-share-positive-early-data-on-lead-mrna-vaccine-candidate-bnt162b2-against-covid-19/>